Efficacy and safety assessments
CRS
The primary endpoint was confirmed ORR, defined as PR or better (≥PR) according to IMWG criteriaAEs were graded according to the NCI CTCAE (version 5.0), except for CRS and ICANS, which were graded according to the criteria of the American Society for Transplantation and Cellular TherapyAll analyses were performed in the 123 patients who received at least one dose of elranatamab, with the exception of CRS and ICANS analyses, which were performed on the 119 patients who received the 12/32 mg step-up regimen.